|
[1] PATTERSON SJ, GEORGE J, STRASSER SI, et al.Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B[J].Gut, 2011, 60 (2) :247-254.
|
|
[2]LEVRERO M, CIMINO L, LAMPERTICO P, et al.Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment:results of the OPTIB Italian multicenter prospective open label study[J].Hepatology, 2010, 52:92A.
|
|
[3] SHELDON J, CAMINO N, RODES B, et al.Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir[J].Antivir Ther, 2005, 10 (6) :727-734.
|
|
[4] AMINI-BAVIL-OLYAEE S, HERBERS U, SHELDON J, et al.The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains[J].Hepatology, 2009, 49 (4) :1158-1165.
|
|
[5] BRUNELLE MN, JACQUARD AC, PICHOUD C, et al.Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir[J].Hepatology, 2005, 41 (6) :1391-1398.
|
|
[6]KOZIEL MJ, PETERS MG.Viral hepatitis in HIV infection[J].N Engl J Med, 2007, 356 (14) :1445-1154.
|
|
[7]GISH RG, LOCARNINI S.Genotyping and genomic sequencing in clinical practice[J].Clin Liver Dis, 2007, 11 (4) :761-795.
|
|
[8]ZOULIM F, LOCARNINI S.Management of treatment failure in chronic hepatitis B[J].J Hepatol, 2012, 56 (Suppl 1) :s112-122.
|
|
[9]ZHENG J, ZENG Z, ZHANG D, et al.Prevalence and significance of hepatitis B reverse transcriptase mutants in different disease stages of untreated patients[J].Liver Int, 2012, 32 (10) :1535-1542.
|
|
[10]RHEE SY, MARGERIDON-THERMET S, NGUYEN MH, et al.Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery[J].Antiviral Res, 2010, 88 (3) :269-275.
|
|
[11]XU Z, LIU Y, XU T, et al.Acute hepatitis B infection associated with drug-resistant hepatitis B virus[J].J Clin Virol, 2010, 48 (4) :270-274.
|
|
[12]GAI HP, SUN WX, YUAN DS, et al.The clinical implications of detecting pre-existing resistance to nucleos (t) ide analogue-based antiviral therapy[J].J Clin Hepatol, 2012, 28 (11) :841-844. (in Chinese) 盖洪鹏, 孙伟翔, 袁德胜, 等.预存耐药对核苷 (酸) 类似物抗病毒治疗应答和耐药的影响[J].临床肝胆病杂志, 2012, 28 (11) :841-844.
|
|
[13]TAN Y, DING K, SU J, et al.The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine:a systematic review and meta-analysis[J].PLoS One, 2012, 7 (3) :e32789.
|
|
[14]MIN XC, MIAO XH, ZHAO SM, et al.The spontaneous YMDD mutation rate in chronic hepatitis B patients[J].Chin J Hepatol, 2009, 17 (12) :887-890. (in Chinese) 闵晓春, 缪晓辉, 赵书民, 等.慢性乙型肝炎病毒感染者病毒YMDD的自然变异[J].中华肝脏病杂志, 2009, 17 (12) :887-890.
|
|
[15]YANG YL, XIAO P, GAO P, et al.Distribution of HBV genotypes and YMDD mutations in e antigen-positive patients[J].J Clin Hepatol, 2012, 28 (6) :428-430. (in Chinese) 杨彦麟, 肖萍, 高鹏, 等.HBeAg阳性患者中乙肝病毒基因型分布及YMDD变异位点分析[J].临床肝胆病杂志, 2012, 28 (6) :428-430.
|
|
[16]YE XG, WANG RL, GUO HB.Detection of YMDD mutant in patients with chronic hepatitis B before treatment[J].Chin J Lab Med, 2002, 25 (4) :248. (in Chinese) 叶晓光, 王若伦, 郭海波.慢性乙型肝炎患者治疗前YMDD变异基因的检测及分析[J].中华检验医学杂志, 2002, 25 (4) :248.
|
|
[17]QIN B, BUDEUS B, CAO L, et al.The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir[J].Antiviral Research, 2013, 97 (2) :93-100.
|
|
[18]van BMMEL F, de MAN RA, Wedemeyer H, et al.Long-term efficacy of tenofovir monotherapy for hepatitis B virus monoinfected patients after failure of nucleoside/nucleotide analogues[J].Hepatology, 2010, 51 (1) :73-80.
|
|
[19]LIANG ZL, LIU Y, SU HL, et al.Mutations possibly associated with tenofovir disoproxil fumarate resistance in 1740 patients with chronic hepatitis B[J].Infect Dis Info, 2009, 22 (4) :207-210. (in Chinese) 梁兆玲, 刘妍, 苏何玲, 等.1740例慢性乙型肝炎患者替诺福韦酯耐药可能相关突变分析[J].传染病信息, 2009, 22 (4) :207-210.
|
DownLoad: